CA2819299A1 - N-substituted azetidine derivatives - Google Patents
N-substituted azetidine derivatives Download PDFInfo
- Publication number
- CA2819299A1 CA2819299A1 CA2819299A CA2819299A CA2819299A1 CA 2819299 A1 CA2819299 A1 CA 2819299A1 CA 2819299 A CA2819299 A CA 2819299A CA 2819299 A CA2819299 A CA 2819299A CA 2819299 A1 CA2819299 A1 CA 2819299A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- fluorine
- optionally substituted
- nitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10196960 | 2010-12-24 | ||
| EP10196960.8 | 2010-12-24 | ||
| PCT/EP2011/073041 WO2012084711A1 (en) | 2010-12-24 | 2011-12-16 | N-substituted azetidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2819299A1 true CA2819299A1 (en) | 2012-06-28 |
Family
ID=43778253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2819299A Abandoned CA2819299A1 (en) | 2010-12-24 | 2011-12-16 | N-substituted azetidine derivatives |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9540361B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2655367B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5886873B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2011347718B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2819299A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2586908T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2012084711A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| EP2791132A4 (en) | 2011-12-14 | 2015-08-05 | Seragon Pharmaceuticals Inc | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| NZ710385A (en) | 2013-02-19 | 2016-10-28 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
| TWI784255B (zh) | 2014-12-18 | 2022-11-21 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| WO2016174551A1 (en) * | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| WO2017059139A1 (en) | 2015-10-01 | 2017-04-06 | Olema Pharmaceuticals, Inc. | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS |
| JP6920295B2 (ja) * | 2015-11-09 | 2021-08-18 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用 |
| DK3386500T3 (da) | 2015-12-09 | 2022-12-12 | Univ Illinois | Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer |
| SG11201806829TA (en) * | 2016-02-15 | 2018-09-27 | Sanofi Sa | 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators |
| EP3440067B1 (en) * | 2016-04-08 | 2021-05-26 | F. Hoffmann-La Roche AG | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109789143A (zh) | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| UA125824C2 (uk) * | 2016-10-24 | 2022-06-15 | Астразенека Аб | 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| EP3541809B1 (en) | 2016-11-17 | 2025-06-25 | Sanofi | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
| JP7229162B2 (ja) | 2017-01-06 | 2023-02-27 | ジー１ セラピューティクス， インコーポレイテッド | 癌の治療に対する併用療法 |
| WO2018138739A1 (en) | 2017-01-27 | 2018-08-02 | Sun Pharma Advanced Research Company Limited | Novel antiestrogenic heterocyclic compounds |
| KR20190117582A (ko) | 2017-02-10 | 2019-10-16 | 쥐원 쎄라퓨틱스, 인크. | 벤조티오펜 에스트로겐 수용체 조정제 |
| GB201706806D0 (en) | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| EP3645001B1 (en) | 2017-06-29 | 2024-07-03 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| EP3434272A1 (en) | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| KR102765922B1 (ko) * | 2018-02-06 | 2025-02-11 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 선택적인 에스트로겐 수용체 분해제로서의 치환된 벤조티오펜 유사체 |
| LT3810283T (lt) | 2018-06-21 | 2023-08-25 | F. Hoffmann-La Roche Ag | 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti |
| DK3847157T3 (da) | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| CA3144791A1 (en) | 2019-07-07 | 2021-01-14 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| CA3160897A1 (en) | 2019-12-09 | 2021-06-17 | Sanofi | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative |
| EP4681715A3 (en) | 2019-12-20 | 2026-01-28 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| CN119823124A (zh) | 2020-03-05 | 2025-04-15 | C4医药公司 | 用于brd9的靶向降解的化合物 |
| MX2022010425A (es) | 2020-03-06 | 2022-09-07 | Olema Pharmaceuticals Inc | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. |
| EP4164653A4 (en) | 2020-06-15 | 2024-06-19 | G1 Therapeutics, Inc. | MORPHIC FORMS OF TRILACICLIB AND METHODS OF PREPARING THE SAME |
| CN116490186B (zh) | 2020-08-05 | 2025-10-31 | C4医药公司 | 用于ret的靶向降解的化合物 |
| GB202015187D0 (en) | 2020-09-25 | 2020-11-11 | Sentinel Oncology Ltd | A pharmaceutical salt |
| IL302152B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| IL302153B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| CN113248455A (zh) * | 2021-05-25 | 2021-08-13 | 湖北科技学院 | 一种3,5-二取代异噁唑类衍生物及其合成方法 |
| BR112023024507A2 (pt) | 2021-05-26 | 2024-02-15 | C4 Therapeutics Inc | Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central |
| AU2022290851A1 (en) | 2021-06-08 | 2023-11-23 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| WO2023059714A1 (en) * | 2021-10-06 | 2023-04-13 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| KR20250055538A (ko) | 2022-08-03 | 2025-04-24 | 브리스톨-마이어스 스큅 컴퍼니 | Ret 단백질을 조정하기 위한 화합물 |
| CN117924262A (zh) * | 2022-10-14 | 2024-04-26 | 中国科学院上海药物研究所 | 二氢苯并噻喃类衍生物及其制备方法和用途 |
| JP2025540906A (ja) | 2022-11-04 | 2025-12-17 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｅｔ－ｌｄｄタンパク質阻害剤 |
| KR20250117789A (ko) | 2022-11-04 | 2025-08-05 | 브리스톨-마이어스 스큅 컴퍼니 | Ret-ldd 단백질 분해제 |
| CN116813603B (zh) * | 2023-06-02 | 2024-10-22 | 成都市第三人民医院 | 一种选择性雌激素受体α降解化合物及其制备方法和应用 |
| CN122206684A (zh) | 2023-06-30 | 2026-06-12 | 默克专利有限公司 | 用于kras蛋白降解的异双功能化合物 |
| WO2026139448A1 (en) | 2024-12-23 | 2026-07-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3983245A (en) * | 1975-02-06 | 1976-09-28 | Smithkline Corporation | Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes |
| US6750213B2 (en) | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
| DOP2002000467A (es) * | 2001-10-10 | 2003-04-15 | Pfizer Prod Inc | 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas |
| TW200304371A (en) * | 2002-02-22 | 2003-10-01 | Akzo Nobel Nv | Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors |
| US20030225132A1 (en) | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
| ATE481397T1 (de) | 2002-04-24 | 2010-10-15 | Merck Sharp & Dohme | Modulatoren des östrogenrezeptors |
| CA2512000C (en) * | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| EP2222638A2 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating inflammation |
-
2011
- 2011-12-16 CA CA2819299A patent/CA2819299A1/en not_active Abandoned
- 2011-12-16 WO PCT/EP2011/073041 patent/WO2012084711A1/en not_active Ceased
- 2011-12-16 ES ES11794797.8T patent/ES2586908T3/es active Active
- 2011-12-16 AU AU2011347718A patent/AU2011347718B2/en not_active Ceased
- 2011-12-16 EP EP11794797.8A patent/EP2655367B1/en active Active
- 2011-12-16 JP JP2013545218A patent/JP5886873B2/ja not_active Expired - Fee Related
- 2011-12-16 US US13/995,237 patent/US9540361B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012084711A1 (en) | 2012-06-28 |
| EP2655367B1 (en) | 2016-07-06 |
| EP2655367A1 (en) | 2013-10-30 |
| AU2011347718B2 (en) | 2016-06-23 |
| ES2586908T3 (es) | 2016-10-19 |
| JP5886873B2 (ja) | 2016-03-16 |
| US9540361B2 (en) | 2017-01-10 |
| JP2014503537A (ja) | 2014-02-13 |
| US20160130262A1 (en) | 2016-05-12 |
| AU2011347718A1 (en) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011347718B2 (en) | N-substituted azetidine derivatives | |
| WO2022268230A1 (zh) | 作为kif18a抑制剂的化合物 | |
| BRPI0610183A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| KR20140103335A (ko) | 신규한 벤조피란 화합물, 조성물 및 이의 용도 | |
| EA018011B1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| CA2849176A1 (en) | Fsh receptor antagonists | |
| US6689798B2 (en) | Benzofuran derivatives | |
| TW201710253A (zh) | 抗雌激素化合物 | |
| BRPI0713743B1 (pt) | Composto, pró-droga, e, composição farmacêutica | |
| CN109265471B (zh) | Fxr受体激动剂 | |
| CN111770924B (zh) | 用于治疗乳腺癌的雌激素受体降解剂 | |
| JP2022537330A (ja) | インダゾール誘導体、その製造方法及び医薬上のその使用 | |
| CN102791688A (zh) | 雌激素受体配体 | |
| JP5947898B2 (ja) | Ｆｓｈ受容体アンタゴニスト | |
| CN111615515A (zh) | 杂环化合物、制备方法及其在医药上的应用 | |
| US20030130340A1 (en) | Novel benzothiophene derivatives | |
| EP2459551B1 (en) | Dihydrobenzoindazoles | |
| US8071589B2 (en) | Dihydrobenzoindazoles | |
| CN119948023A (zh) | 含哌啶多环类衍生物调节剂、其制备方法和应用 | |
| JP4304732B2 (ja) | エストロゲンレセプターβアイソフォーム活性化剤 | |
| US20160052937A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine compound | |
| US10155259B2 (en) | FSH receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20161207 |
|
| FZDE | Dead |
Effective date: 20200831 |